Market research

EVMN Evommune, Inc.

NYSE USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 383M
P/E ratio: Not available
Analyst target: 24.125
Dividend yield: Not available
Beta: Not available

Loading price history…

Profile

Company facts

Exchange: NYSE
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: US30054Y1073
Market cap: 383M
P/E ratio: Not available
Analyst target: 24.125
Dividend yield: Not available
Beta: Not available

About

About Evommune, Inc.

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is headquartered in Palo Alto, California.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about EVMN.

EVMN Evommune, Inc.

Price & volume

Company facts

About Evommune, Inc.

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet